Ask AI
TROP2 and TIGIT Transforming Lung Cancer Treatment

CE / CME

Targeting TROP-2 and TIGIT: Experts Discuss How ADCs and Immunotherapeutic Combinations Are Transforming Lung Cancer Treatment

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: September 04, 2025

Expiration: March 03, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

When discussing new clinical data with your colleagues, in which of the following patient populations with locally advanced or metastatic NSCLC would you tell them datopotamab deruxtecan is currently FDA approved?

2.

Based on ARC-10 trial in patients with treatment-naive PD-L1–high NSCLC, which statement best describes the clinical activity with domvanalimab + zimberelimab vs zimberelimab alone?

3.

Based on eligibility criteria for the phase III EVOKE-SCLC-04 trial with sacituzumab govitecan vs SoC, which of the following patients with ES-SCLC could be considered for enrollment on this trial?

4.

How confident are you in addressing disparities in access to novel therapies and clinical trials for rural, Black, and underserved patients with lung cancer?